News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diopsys Inc. to Introduce OCT Enhancement Software



9/5/2012 10:01:15 AM

PINE BROOK, N.J., Sept. 4, 2012 /PRNewswire/ -- Eye care providers will soon have a new option for improving the analysis of their current Optical Coherence Tomography (OCT) images. The new Diopsys® CORDA software uses existing OCT images to give eye care professionals a better understanding of the health of the Retinal Nerve Fiber Layer (RNFL).

According to literature, current algorithms in OCT technology may overstate the RNFL thickness due to patient physiology and other test related limitations. The Diopsys® CORDA software utilizes existing images to better discriminate different components, leading to a more accurate assessment of the RNFL.

Diopsys has finalized the CORDA software with input from Wills Eye Institute of Philadelphia. A recent poster presented at The Association for Research in Vision and Ophthalmology (ARVO) conference concluded that the CORDA software correlates well with RNFL thickness which helps to better detect glaucomatous changes on OCT images. Alberto Gonzalez, MD, Research Director for Diopsys says, "The Diopsys® CORDA software will improve the analysis of OCT images, helping doctors detect vision disorders earlier so treatment can begin sooner."

The new CORDA software will afford eye care specialists the ability to greatly enhance the clinical utility of their existing OCT devices without investing in costly hardware upgrades. Diopsys® CORDA has been proven to work with existing OCT images from Carl Zeiss, Meditec, Heidelberg Engineering, Optovue and Topcon devices.

To be added to a contact list for further information on the release of the Diopsys® CORDA software, please visit www.diopsys.com/CORDAinfo.

About Diopsys

Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing devices utilizing Visual Evoked Potential (VEP) technology.

SOURCE Diopsys, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES